

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



TG101209

Item No. 14696

CAS Registry No.: 936091-14-4

Formal Name: N-(1,1-dimethylethyl)-3-

[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]

amino]-4-pyrimidinyl]amino]-

benzenesulfonamide

 $C_{26}H_{35}N_7O_2S$ MF:

509.7 FW: **Purity:** ≥98%

UV/Vis.: λ_{max} : 282 nm A crystalline solid Supplied as:

-20°C Storage:

Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when

stored properly

Laboratory Procedures

TG101209 is supplied as a crystalline solid. A stock solution may be made by dissolving the TG101209 in the solvent of choice. TG101209 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of TG101209 in these solvents is approximately 0.12, 12.5, and 16 mg/ml, respectively.

TG101209 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, TG101209 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. TG101209 has a solubility of approximately0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

TG101209 is a potent inhibitor of the tyrosine kinases janus kinase (JAK) 2, FMS-like tyrosine kinase 3, proto-oncogene RET, and JAK3 (IC_{50} = 6, 25, 17, and 169 nM, respectively). Through these effects, it induces cell cycle arrest and apoptosis in leukemic cell lines and CD45⁺ myeloma cells.^{1,2}

References

- 1. Pardanani, A., Lasho, T., Levine, R.L., et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 21(8), 1658-1668 (2007).
- 2. Ramakrishnan, V., Kimlinger, T., Haug, J., et al. TG101209, a novel JAK2 inhibitor, has significant in-vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. Am. J. Hematol. 85(9), 675-686 (2010).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

al should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution

WARRANTY AND LIMITATION OF REMEDY

Suyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/25/2016

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM